JP2022529166A5 - - Google Patents
Info
- Publication number
- JP2022529166A5 JP2022529166A5 JP2021561778A JP2021561778A JP2022529166A5 JP 2022529166 A5 JP2022529166 A5 JP 2022529166A5 JP 2021561778 A JP2021561778 A JP 2021561778A JP 2021561778 A JP2021561778 A JP 2021561778A JP 2022529166 A5 JP2022529166 A5 JP 2022529166A5
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- hydroxy
- pharmaceutically acceptable
- cyclopenta
- oxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962836019P | 2019-04-18 | 2019-04-18 | |
| US62/836,019 | 2019-04-18 | ||
| US201962946191P | 2019-12-10 | 2019-12-10 | |
| US62/946,191 | 2019-12-10 | ||
| PCT/US2020/028579 WO2020214853A1 (en) | 2019-04-18 | 2020-04-16 | Tetrahydro-1h-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529166A JP2022529166A (ja) | 2022-06-17 |
| JP2022529166A5 true JP2022529166A5 (enExample) | 2023-04-18 |
| JP7581236B2 JP7581236B2 (ja) | 2024-11-12 |
Family
ID=71094790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561778A Active JP7581236B2 (ja) | 2019-04-18 | 2020-04-16 | 低酸素誘導因子２（アルファ）阻害剤としてのテトラヒドロ－１Ｈ－シクロペンタ［ｃｄ］インデン誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US20200361855A1 (enExample) |
| EP (1) | EP3956299A1 (enExample) |
| JP (1) | JP7581236B2 (enExample) |
| KR (1) | KR20210154191A (enExample) |
| CN (3) | CN113874350B (enExample) |
| AU (1) | AU2020260130C1 (enExample) |
| CA (1) | CA3136650A1 (enExample) |
| IL (1) | IL287258B2 (enExample) |
| MX (1) | MX2021012549A (enExample) |
| SG (1) | SG11202111118YA (enExample) |
| TW (1) | TWI871313B (enExample) |
| UA (1) | UA128792C2 (enExample) |
| WO (1) | WO2020214853A1 (enExample) |
| ZA (1) | ZA202108270B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12171741B2 (en) | 2018-09-11 | 2024-12-24 | Nikang Therapeutics, Inc. | 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors |
| WO2020081695A1 (en) | 2018-10-17 | 2020-04-23 | Nikang Therapeutics, Inc. | Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors |
| IL287258B2 (en) | 2019-04-18 | 2026-01-01 | Nikang Therapeutics Inc | Inhibitors as tetrahydro-1h-cyclopenta[cd] indene derivatives as hypoxia inducible factor -2alpha |
| US20220274914A1 (en) * | 2019-07-22 | 2022-09-01 | Nikang Therapeutics, Inc. | Tricyclic derivatives as hypoxia inducible factor-2(alpha) inhibitors |
| CN119118872A (zh) | 2020-03-19 | 2024-12-13 | 艾库斯生物科学有限公司 | 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物 |
| US11420936B2 (en) | 2020-04-16 | 2022-08-23 | Nikang Therapeutics, Inc. | Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases |
| AU2021256998A1 (en) * | 2020-04-16 | 2022-10-20 | Nikang Therapeutics, Inc. | Hypoxia Inducible Factor-2(alpha) inhibitors and their use in the treatment of diseases |
| CN114315552B (zh) * | 2020-09-30 | 2024-08-02 | 江西济民可信集团有限公司 | 三并环类化合物及其制备方法和应用 |
| WO2022082329A1 (en) * | 2020-10-19 | 2022-04-28 | Nikang Therapeutics, Inc. | Processes of preparing 3-fluoro-5- ( ( (1s, 2ar) -1, 3, 3, 4, 4-pentafluoro-2a-hydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) -benzonitrile |
| WO2022082337A1 (en) | 2020-10-19 | 2022-04-28 | Nikang Therapeutics, Inc. | Process of preparing 3-fluoro-5 ( ( (1r, 2ar) -3, 3, 4, 4-tetrafluoro-1, 2a-dihydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) benzonitrile |
| WO2022086882A1 (en) | 2020-10-21 | 2022-04-28 | Nikang Therapeutics, Inc. | Diagnostic and therapeutic methods for treatment of cancer with a hif-2(alpha) inhibitor |
| US20220251218A1 (en) * | 2021-02-10 | 2022-08-11 | Gnt Biotech & Medicals Corporation | Pharmaceutical combination and method for overcoming immune suppression or stimulating immune response against cancer |
| CN121824485A (zh) * | 2021-02-23 | 2026-04-10 | 上海济煜医药科技股份有限公司 | 作为HIF2α抑制剂的三并环类化合物及其制备方法和应用 |
| US12145901B1 (en) | 2021-09-17 | 2024-11-19 | Arcus Biosciences, Inc. | Process for preparing tetralin compounds |
| WO2023060431A1 (en) | 2021-10-12 | 2023-04-20 | Nikang Therapeutics, Inc. | Processes of making 3-fluoro-5- ( ( (1s, 2ar) -1, 3, 3, 4, 4-pentafluoro-2a-hydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) -benzonitrile and polymorphs thereof |
| CN116457335A (zh) | 2021-10-12 | 2023-07-18 | 尼坎治疗公司 | 制备3-氟-5-(((1S,2aR)-1,3,3,4,4-五氟-2a-羟基-2,2a,3,4-四氢-1H-环戊二烯并[cd]茚-7-基)氧基)苄腈及其多晶型物的方法 |
| EP4419089A4 (en) * | 2021-10-18 | 2025-09-10 | Nikang Therapeutics Inc | HYPOXIA-INDUCIBLE FACTOR 2-(ALPHA) INHIBITORS FOR THE TREATMENT OF BLADDER CANCER |
| WO2023070483A1 (en) | 2021-10-29 | 2023-05-04 | Nikang Therapeutics, Inc. | PROCESSES OF MAKING 3-FLUORO-5- ( ( (1R, 2S, 2aS) -1, 2, 3, 3, 4, 4-HEXAFLUORO-2A-HYDROXY-2, 2A, 3, 4-TETRAHYDRO-1H-CYCLOPENTA [CD] INDEN-7-YL) -OXY) -BENZONITRILE AND POLYMORPHS THEREOF |
| WO2024240240A1 (zh) * | 2023-05-24 | 2024-11-28 | 江苏恩华药业股份有限公司 | 一种咪唑衍生物、中间体、制备方法及其应用 |
| WO2025231006A1 (en) | 2024-05-03 | 2025-11-06 | Nikang Therapeutics, Inc. | Pharmaceutical compositions of 3-fluoro-5-(((1s,2ar)-1,3,3,4,4- pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1h- cyclopenta[cd]inden-7-yl)oxy)-benzonitrile |
| WO2025230942A1 (en) | 2024-05-03 | 2025-11-06 | Nikang Therapeutics, Inc. | Pharmaceutical compositions of 3-fluoro-5-(((ls,2ar)-l,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1h-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile |
| WO2025235034A1 (en) * | 2024-05-04 | 2025-11-13 | Nikang Therapeutics, Inc. | 3-fluoro-5-(((ls,2ar)-1,3,3,4, 4-pentafluoro-2a-hydroxy-2,2a, 3,4-tetrahydro-lh-cyclopenta[cd]inden-7- yl)oxy)- benzonitrile dosing regimen for use in the treatment of cancer |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100383835B1 (ko) | 1996-06-26 | 2003-08-27 | 쥬가이 세이야쿠 가부시키가이샤 | 신장질환치료제및장기보존제 |
| WO2005118580A2 (en) | 2004-05-12 | 2005-12-15 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health | Tricyclic compounds as inhibitors of the hypoxic signaling pathway |
| US8703795B2 (en) | 2005-03-02 | 2014-04-22 | Fibrogen, Inc. | Thienopyridine compounds, and methods of use thereof |
| WO2012170439A1 (en) | 2011-06-06 | 2012-12-13 | The Ohio State University | Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| CN104024227B8 (zh) | 2011-07-22 | 2025-07-29 | 北京贝美拓新药研发有限公司 | 抑制脯氨酸羟化酶活性的化合物的晶型及其应用 |
| PL3417851T3 (pl) * | 2013-09-09 | 2020-12-14 | Peloton Therapeutics, Inc. | Etery arylowe i ich zastosowanie |
| US9884843B2 (en) | 2013-12-16 | 2018-02-06 | Peloton Therapeutics, Inc. | Cyclic sulfone and sulfoximine analogs and uses thereof |
| WO2016057242A1 (en) | 2014-10-10 | 2016-04-14 | The Board Of Regents Of The University Of Texas System | HIF-2α INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS |
| US10278942B2 (en) | 2015-03-11 | 2019-05-07 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
| WO2016144825A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
| WO2016144826A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
| WO2016168510A1 (en) | 2015-04-17 | 2016-10-20 | Peloton Therapeutics, Inc. | Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
| US9796697B2 (en) * | 2015-06-12 | 2017-10-24 | Peloton Therapeutics, Inc. | Tricyclic inhibitors of HIF-2-alpha and uses thereof |
| US20190048421A1 (en) | 2015-09-21 | 2019-02-14 | The Board Of Regents Of The University Of Texas System | Biomarkers of response to hif-2-alpha inhibition in cancer and methods for the use thereof |
| WO2018031680A1 (en) * | 2016-08-10 | 2018-02-15 | Fronthera U.S. Pharmaceuticals Llc | Novel compounds, uses and methods for their preparation |
| JP2020533396A (ja) * | 2017-09-15 | 2020-11-19 | クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド | Ｇｓｋ１２７８８６３の結晶形及びその製造方法並びに医薬用途 |
| EP3774709A4 (en) | 2018-03-28 | 2021-12-22 | Peloton Therapeutics, Inc. | METHOD FOR REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM USING INHIBITORS OF HIF-2-ALPHA |
| US12171741B2 (en) | 2018-09-11 | 2024-12-24 | Nikang Therapeutics, Inc. | 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors |
| WO2020081695A1 (en) | 2018-10-17 | 2020-04-23 | Nikang Therapeutics, Inc. | Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors |
| IL287258B2 (en) | 2019-04-18 | 2026-01-01 | Nikang Therapeutics Inc | Inhibitors as tetrahydro-1h-cyclopenta[cd] indene derivatives as hypoxia inducible factor -2alpha |
| US20220274914A1 (en) | 2019-07-22 | 2022-09-01 | Nikang Therapeutics, Inc. | Tricyclic derivatives as hypoxia inducible factor-2(alpha) inhibitors |
| AU2021256998A1 (en) | 2020-04-16 | 2022-10-20 | Nikang Therapeutics, Inc. | Hypoxia Inducible Factor-2(alpha) inhibitors and their use in the treatment of diseases |
| US11420936B2 (en) | 2020-04-16 | 2022-08-23 | Nikang Therapeutics, Inc. | Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases |
| WO2022082329A1 (en) | 2020-10-19 | 2022-04-28 | Nikang Therapeutics, Inc. | Processes of preparing 3-fluoro-5- ( ( (1s, 2ar) -1, 3, 3, 4, 4-pentafluoro-2a-hydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) -benzonitrile |
| WO2022082337A1 (en) | 2020-10-19 | 2022-04-28 | Nikang Therapeutics, Inc. | Process of preparing 3-fluoro-5 ( ( (1r, 2ar) -3, 3, 4, 4-tetrafluoro-1, 2a-dihydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) benzonitrile |
| CN116457335A (zh) | 2021-10-12 | 2023-07-18 | 尼坎治疗公司 | 制备3-氟-5-(((1S,2aR)-1,3,3,4,4-五氟-2a-羟基-2,2a,3,4-四氢-1H-环戊二烯并[cd]茚-7-基)氧基)苄腈及其多晶型物的方法 |
| EP4419089A4 (en) | 2021-10-18 | 2025-09-10 | Nikang Therapeutics Inc | HYPOXIA-INDUCIBLE FACTOR 2-(ALPHA) INHIBITORS FOR THE TREATMENT OF BLADDER CANCER |
-
2020
- 2020-04-16 IL IL287258A patent/IL287258B2/en unknown
- 2020-04-16 KR KR1020217037203A patent/KR20210154191A/ko active Pending
- 2020-04-16 CN CN202080027716.4A patent/CN113874350B/zh active Active
- 2020-04-16 EP EP20733066.3A patent/EP3956299A1/en active Pending
- 2020-04-16 WO PCT/US2020/028579 patent/WO2020214853A1/en not_active Ceased
- 2020-04-16 US US16/851,018 patent/US20200361855A1/en not_active Abandoned
- 2020-04-16 JP JP2021561778A patent/JP7581236B2/ja active Active
- 2020-04-16 SG SG11202111118YA patent/SG11202111118YA/en unknown
- 2020-04-16 CA CA3136650A patent/CA3136650A1/en active Pending
- 2020-04-16 AU AU2020260130A patent/AU2020260130C1/en active Active
- 2020-04-16 CN CN202411099450.0A patent/CN118993938A/zh active Pending
- 2020-04-16 CN CN202411099453.4A patent/CN118993939A/zh active Pending
- 2020-04-16 UA UAA202105642A patent/UA128792C2/uk unknown
- 2020-04-16 MX MX2021012549A patent/MX2021012549A/es unknown
- 2020-04-17 TW TW109113096A patent/TWI871313B/zh active
-
2021
- 2021-03-30 US US17/218,129 patent/US11267782B2/en active Active
- 2021-07-15 US US17/377,356 patent/US20210347729A1/en not_active Abandoned
- 2021-10-26 ZA ZA2021/08270A patent/ZA202108270B/en unknown
-
2022
- 2022-02-11 US US17/670,423 patent/US11753366B2/en active Active
-
2023
- 2023-07-12 US US18/351,283 patent/US12391642B2/en active Active
-
2025
- 2025-07-15 US US19/270,361 patent/US20250340508A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022529166A5 (enExample) | ||
| TWI430793B (zh) | 利用免疫調節化合物供治療及管控癌症及其它疾病之方法及組合物 | |
| AU2021202875B2 (en) | Antiproliferative compounds, and their pharmaceutical compositions and uses | |
| TWI415610B (zh) | ３-（４-胺基-１-酮基-１，３-二氫-異吲哚-２-基）-哌啶-２，６-二酮在治療特定白血病之用途 | |
| US7816393B2 (en) | Isoindoline compounds and methods of their use | |
| RS51567B (sr) | Upotreba 3-(4-amino-1-okso-1,3-dihidro-izoindol-2-il)-piperidin-2,6-diona za lečenje limfoma mantle ćelija | |
| KR20180103918A (ko) | 암을 치료하는 방법 | |
| KR20180023968A (ko) | 혈액암 및 충실성 종양의 치료를 위한 병용 요법 | |
| WO2019006299A1 (en) | COMPOSITIONS AND METHODS FOR THE USE OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE | |
| KR20220035955A (ko) | Sting 작용제로서의 거대고리 화합물 및 이의 방법 및 용도 | |
| US20100129363A1 (en) | Methods and compositions using pde4 inhibitors for the treatment and management of cancers | |
| WO2019136016A1 (en) | Isotopologues of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| EP3813870B1 (en) | Ccr5 inhibitor for use in treating cancer | |
| JP6469077B2 (ja) | ４−アミノ−２−（２，６−ジオキソ−ピペリジン３−イル）−イソインドリン−１，３−ジオンを使用する中枢神経の癌の治療及び管理のための方法及び組成物 | |
| CA3125189A1 (en) | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5yl) methyl)-2,2-difluoroacetamide | |
| CA3157196A1 (en) | Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide | |
| JP2017537962A (ja) | （１Ｅ，４Ｅ）−２−アミノ−Ｎ，Ｎ−ジプロピル−８−（４−（ピロリジン−１−カルボニル）フェニル）−３Ｈ−ベンゾ［ｂ］アゼピン−４−カルボキサミドを含む固体形態、その組成物、およびその使用 | |
| JP2018535992A (ja) | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを使用するサイクリング療法 | |
| MXPA06012698A (es) | Metodos y composiciones que utilizan farmacos inhibidores de citocina selectiva para el tratamiento y manejo de canceres y otras enfermedades. | |
| HK40051637B (en) | Antiproliferative compounds for use in the treatment of leukemia | |
| HK40033324A (en) | Isotopologues of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| HK1262667B (en) | Antiproliferative compounds, and their pharmaceutical compositions and uses | |
| HK1262667A1 (en) | Antiproliferative compounds, and their pharmaceutical compositions and uses |